Profile of Sickle Cell Disease Patients Admitted for Management of an Acute Complication in the Pediatrics Department of the Cocody University Hospital (CHU)
Introduction: Sickle-cell anemia is the source of numerous potentially fatal complications in the absence of adequate management. The aim was to contribute to improving the management of acute complications of sickle cell disease. Methodology: This was a retrospective descriptive study. It took place in the pediatrics department of the Cocoy University Hospital (CHU) from January 1 to December 31, 2022. We included all patients hospitalized for management of acute complications of sickle cell disease. Results: We identified 81 cases. The hospital prevalence of acute complications of sickle cell disease was 17.48%. The mean age was 6 years 5 months, with a sex ratio of 1.02. In 92.6% of cases, children were known to have sickle cell disease prior to hospitalization, and the mean age of discovery was 34.01 months ± 29.273. The patients’ electrophoretic profile was dominated by the SS form in 45.7% of cases and SFA2 in 32.1%. Follow-up was irregular in 61.7% of cases. Anemia, fever, pain and respiratory difficulty were present in 80.3%, 69%, 67.9% and 32.1% of cases respectively. APS was diagnosed in 6 patients. Infectious complications were dominated by malaria (39.5%). The majority of our children received antibiotic therapy (76.5%). Surgical treatment was undertaken in 5 patients with osteoarticular infections. The outcome was favorable in 91.40% of cases, with 2 cases of death. Average hospital stay was 8.20 days. Conclusion: Improving the vital prognosis of children with sickle cell disease requires effective diagnosis and management of acute complications.
References
[1]
Tembiné, K., Diallo, B., Dicko, H., Beye, S.A., Traoré, S., Guindo, A., et al. (2022) Complications aiguës de la drépanocytose en réanimation: Étude transversale rétrospective au Centre Hospitalier universitaire du Point G, Mali. PAMJClinicalMedicine, 8, Article No. 49. https://doi.org/10.11604/pamj-cm.2022.8.49.31899
[2]
Weatherall, D.J. and Clegg, J.B. (2001) Inherited Haemoglobin Disorders: An Increasing Global Health Problem. Bulletin of the World Health Organization, 70, 704-712.
[3]
Renaudier, P. (2014) Physiopathology of Sickle Cell Disease. TransfusionCliniqueetBiologique, 21, 178-181. https://doi.org/10.1016/j.tracli.2014.08.139
[4]
Rahimy, M.C. (2005) Problems Posed by Transfusion in Children with Sickle Cell Disease in Africa. ArchivesdePédiatrie, 12, 802-804. https://doi.org/10.1016/j.arcped.2005.04.038
[5]
Cabannes, R. and Sangaré, A. (1976) Therapeutics of Sickle Cell Crisis in Children. Médecined’Afrique Noire, 23, 225-236.
[6]
Alain, F., Rahariniainasoa, A.A., Rakotondratsara, M.A., et al. (2022) Epidemio-Clinical Study of Sickle-Cell Anemia in Children at the Pediatric Department of the Mahajanga University Hospital Center. Revue malgache de pédiatrie, 5, 98-105.
[7]
Dah Sanssan, F. (2020) Complications of Sickle Cell Disease: Clinical and Therapeutic Aspects in the Pediatric Department of the CHU de Cocody from 2020-2021. Med. Thesis, UFR Medical Sciences University Félix Houphouët-Boigny, 120 p.
[8]
Keita, I. (2020) Epidemioclinical Aspects of Sickle Cell Disease in the Pediatric Ward of Sikasso Hospital. Med., Thesis, Faculty of Medicine and Odonto-Stomatology, University of Sciences, Techniques and Technologies, 95 p.
[9]
Kpakoutou, N.A. (2020) Pulmonary Complications in Children with Major Sickle Cell Disease in the Pediatric Department of CHU Gabriel. Med. Thesis, Faculty of Medicine and Odonto-Stomatology, University of Sciences, Techniques and Technologies, 97 p.
[10]
Berthet, S., Monpoux, F., Soummer, A., Bérard, E., Sarles, J. and Badens, C. (2010) Dépistage néonatal de la drépanocytose au CHU de Nice: Bilan des 8 dernières années. ArchivesdePédiatrie, 17, 1652-1656. https://doi.org/10.1016/j.arcped.2010.09.011
[11]
Akolly, D.A.E., Djadou, K.E., Guedenon, K.M., et al. (2021) Hospital Morbidity in Children with Sickle Cell Disease at CHU Sylvanus Olympio (Lomé). Médecined’Afrique Noire, 6802, 105-111.
[12]
Bégué, P. and Castello-Herbreteau, B. (2001) Sickle-Cell Anemia: From Child to Teenager 2001. Sickle Cell Disease and b-Thalassemia Day. Bulletin de la Societe de PathologieExotique, 94, 85-89.
[13]
De Montalembert, M. and Tshilolo, L. (2007) Are Therapeutic Advances in the Management of Sickle Cell Disease Applicable in Sub-Saharan Africa? Médecinetropicale, 67, 612-616.
[14]
Barry, I.K., Camara, E., Diallo, M.L., Ondima, L.H.M. and Dia, H. (2019) Infectious Complications of Major Sickle Cell Disease in the Department of Pediatrics at the National Hospital of France Donka à Conakry (Guinée): About 34 Cases. Health Sciences and Disease, 20, 1-3.
[15]
Cox, S.E., Makani, J., Fulford, A.J., Komba, A.N., Soka, D., Williams, T.N., et al. (2011) Nutritional Status, Hospitalization and Mortality among Patients with Sickle Cell Anemia in Tanzania. Haematologica, 96, 948-953. https://doi.org/10.3324/haematol.2010.028167
[16]
Fauroux, B., Muller, M.-H., Quinet, B. and Begue, P. (1998) The Sickle Cell Lung: From Child to Adult. Revue des Maladies Respiratoires, 15, 159-168.
[17]
El Badaoui, G. (2008) Serious Complications of Sickle Cell Disease. Med. Thesis, University Mohamed V.
[18]
Mongardon, M., Habibi, A., Vodovar, D., Cherait, C., Haouachel, H., Galacteros, F., et al. (2015) Acute Sickle Cell Crisis. SFAR, 1-16.
[19]
French Health Authority (2006) Management of Sickle Cell Disease in Children and Adolescents. Journal de Pédiatrie et de Puériculture, 19, 71-84.
[20]
Steinberg, M.H., Barton, F., Castro, O., Pegelow, C.H., Ballas, S.K., Kutlar, A., et al. (2003) Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits up to 9 Years of Treatment. JAMA, 289, 1645-1651. https://doi.org/10.1001/jama.289.13.1645
[21]
Diallo, D.A. (2008) Sickle Cell Disease in Africa: Issues and Strategies for Improving Follow-Up and Quality of Life in Sickle Cell Disease. Bulletin de l’Académie Nationale de Médecine, 192, 1361-1373.
